Fulgent Genetics, Inc. FLGT Therapeutic Development — Total Assets
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s therapeutic development — total assets?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — total assets of $109.14M in Q1 2026.
- How has Fulgent Genetics, Inc.'s therapeutic development — total assets changed year-over-year?
- Fulgent Genetics, Inc.'s therapeutic development — total assets increased by 22.8% year-over-year, from $88.9M to $109.14M.
- What does therapeutic development — total assets mean?
- Represents the total economic resources controlled by the therapeutic development segment used to support drug discovery and clinical research activities. This metric tracks the capital intensity required to maintain the segment's research infrastructure and intellectual property portfolio.